SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX)

SCIENTURE HOLDINGS, INC.

NASDAQ: SCNX (Scienture Holdings, Inc.)

Last update: 13 Dec, 1:29AM

0.605

0.00 (-0.13%)

Add to watchlist

Previous Close	0.606
Open	0.611
Volume	704,465
Avg. Volume (3M)	22,029,687
Market Cap	24,597,898

Price / Earnings (TTM)	0.807
Price / Earnings (Forward)	21.83
Price / Sales	9.96
Price / Book	0.250

52 Weeks Range	0.461 (-23%) — 8.19 (1252%)
Earnings Date	7 Aug 2025 - 11 Aug 2025

Market Trend

		Short Term	Medium Term
Industry	Pharmaceutical Retailers (US)	Mixed	Mixed
	Pharmaceutical Retailers (Global)	Mixed	Bearish
Stock	Scienture Holdings, Inc.	-	-

AIStockmoo Score

-0.6

Analyst Consensus	0.0
Insider Activity	NA
Price Volatility	-2.0
Technical Moving Averages	0.0
Technical Oscillators	-0.5
Average	-0.63

Similar Stocks

Stock	Market Cap	DY	P/E (TTM)	P/B
SCNX	25 M	-	0.807	0.250
HKPD	8 M	-	-	1.75
HITI	219 M	-	-	2.34
WBA	10 B	4.34%	-	1.44
PETS	73 M	-	-	1.72
RDGT	43 M	-	-	1.86

Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
Sector	Healthcare
Industry	Pharmaceutical Retailers
Investment Style	Small Core
% Held by Insiders	32.59%
% Held by Institutions	1.35%

No data within this time range.

Date	Type	Details
22 Dec 2025	Announcement	SCIENTURE Provides Update on the Commercial Launch of REZENOPY®, the Highest Strength Naloxone HCl Life-Saving Opioid Overdose Emergency Treatment Approved by the FDA
10 Dec 2025	Announcement	SCIENTURE and BlinkRx Announce Strategic Collaboration to Expand Patient Access to Arbli™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium
08 Dec 2025	Announcement	Updated Lineup Announced for iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025
02 Dec 2025	Announcement	SCIENTURE to Participate in the iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9–10, 2025
01 Dec 2025	Announcement	iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025
13 Nov 2025	Announcement	SCIENTURE Reports Q3 2025 Financial Results and Provides Business Update
04 Nov 2025	Announcement	SCIENTURE Announces Addition of Arbli™ (Losartan Potassium) to Formularies of Major National Health Plans
23 Oct 2025	Announcement	SCIENTURE Announces Start of Commercial Sales and Fulfillment of First Orders for Arbli™ (Losartan Potassium)
16 Oct 2025	Announcement	SCIENTURE’S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers
08 Oct 2025	Announcement	SCIENTURE Holdings Announces Full Repayment and Conversion of Outstanding Debentures, Strengthening Balance Sheet
01 Oct 2025	Announcement	SCIENTURE Secures Multiple Commercial GPO Agreements, Expanding U.S. Market Access for Arbli™ (losartan potassium) to more than 2500 Healthcare Institutions
Show more

Ex Date	Announcement Date	Payment Date	Details
19 Jul 2024	08 Jul 2024	24 Jul 2024	1.5 Cash
25 Mar 2024	28 Feb 2024	22 Mar 2024	8 Cash

Annual Dividend Yield

Year	Annual Dividend ($)	Frequency/Year	Yield %
2024	9.50	2	157.03

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Realized Profit	-
Unrealized Profit	-
Dividend Received 2025	-
Total Profit	-
Avg. Return	-
Quantity (Buy)	-
Avg. Price (Buy)	-
Quantity (Sold)	-
Avg. Price (Sold)	-

No stocks matching your criteria

Operating Margin (TTM)	-34,814.94%
Diluted EPS (TTM)	0.660
Quarterly Revenue Growth (YOY)	-58.70%

Total Debt/Equity (MRQ)	4.70%
Current Ratio (MRQ)	1.05
Operating Cash Flow (TTM)	-7.03 M
Levered Free Cash Flow (TTM)	-6.06 M

Return on Assets (TTM)	-14.99%
Return on Equity (TTM)	-35.92%

Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)